The PROSPER study (PROspective Study of Pravastatin in the Elderly at Risk) is an ongoing collaboration between the LUMC in The Netherlands, the Glasgow University in Scotland, and the Cork University in Ireland. Between 1997 and 1999, 5,804 people between 70-82 years old at high risk for vascular disease were selected to participate in this study. Half of the participants received the cholesterol-lowering drug pravastatin and the other half received a placebo. In addition, recent years have seen the addition of a genome-wide association study (the PHArmacogenomic Study of Statins in the Elderly at risk (PHASE)), which included 5,244 PROSPER participants.
This unprecedented large randomized controlled trial in elderly people was set up to test the hypothesis that cholesterol-lowering drugs have clinical benefit in older populations with an increased risk for vascular disease. While this study was completed in 2002, the data are still utilized to find genetic and biological markers that determine the risk of vascular diseases, cognitive decline, and cancer.
For more information on this study you can contact dr. Stella Trompet, email@example.com.